6.6% revenue growth, 54% EBITDA margin, P&C premium tailwind. Target $235 vs current $205 = +14.6% upside — just below 15% threshold. Exceptional quality compounder with durable moat. Missing: upside only 14.6%, just shy of the 20% required for conv 8.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
20.0%/yr
±4.0% · revenue growth to justify current price
FCF-Based Reverse DCF
10.5%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~7h).
Eagle will generate this view by the next trading session (~7h).
Verisk delivered 6.6% revenue growth in FY2025 (.07B), with underwriting +7.7% and claims +4.1%. EBITDA margin stable at 54.3% despite pricing of new debt. Insurance remains 70% of revenue (primarily ...